54 results on '"Tremblay M"'
Search Results
2. Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein.
- Author
-
Lemke CT, Titolo S, von Schwedler U, Goudreau N, Mercier JF, Wardrop E, Faucher AM, Coulombe R, Banik SS, Fader L, Gagnon A, Kawai SH, Rancourt J, Tremblay M, Yoakim C, Simoneau B, Archambault J, Sundquist WI, and Mason SW
- Subjects
- Benzimidazoles pharmacology, Benzodiazepines pharmacology, Capsid metabolism, Cell Line, Gene Products, gag chemistry, Gene Products, gag genetics, Gene Products, gag metabolism, HIV Infections drug therapy, HIV-1 chemistry, HIV-1 genetics, HIV-1 physiology, Humans, Protein Structure, Tertiary, Virus Assembly drug effects, Anti-HIV Agents pharmacology, Capsid drug effects, Gene Products, gag antagonists & inhibitors, HIV Infections virology, HIV-1 drug effects
- Abstract
The emergence of resistance to existing classes of antiretroviral drugs necessitates finding new HIV-1 targets for drug discovery. The viral capsid (CA) protein represents one such potential new target. CA is sufficient to form mature HIV-1 capsids in vitro, and extensive structure-function and mutational analyses of CA have shown that the proper assembly, morphology, and stability of the mature capsid core are essential for the infectivity of HIV-1 virions. Here we describe the development of an in vitro capsid assembly assay based on the association of CA-NC subunits on immobilized oligonucleotides. This assay was used to screen a compound library, yielding several different families of compounds that inhibited capsid assembly. Optimization of two chemical series, termed the benzodiazepines (BD) and the benzimidazoles (BM), resulted in compounds with potent antiviral activity against wild-type and drug-resistant HIV-1. Nuclear magnetic resonance (NMR) spectroscopic and X-ray crystallographic analyses showed that both series of inhibitors bound to the N-terminal domain of CA. These inhibitors induce the formation of a pocket that overlaps with the binding site for the previously reported CAP inhibitors but is expanded significantly by these new, more potent CA inhibitors. Virus release and electron microscopic (EM) studies showed that the BD compounds prevented virion release, whereas the BM compounds inhibited the formation of the mature capsid. Passage of virus in the presence of the inhibitors selected for resistance mutations that mapped to highly conserved residues surrounding the inhibitor binding pocket, but also to the C-terminal domain of CA. The resistance mutations selected by the two series differed, consistent with differences in their interactions within the pocket, and most also impaired virus replicative capacity. Resistance mutations had two modes of action, either directly impacting inhibitor binding affinity or apparently increasing the overall stability of the viral capsid without affecting inhibitor binding. These studies demonstrate that CA is a viable antiviral target and demonstrate that inhibitors that bind within the same site on CA can have distinct binding modes and mechanisms of action.
- Published
- 2012
- Full Text
- View/download PDF
3. Thermoreversible gel as a candidate barrier to prevent the transmission of HIV-1 and herpes simplex virus type 2.
- Author
-
Piret J, Gagné N, Perron S, Désormeaux A, Tremblay MJ, Gourde P, Omar RF, and Bergeron AM
- Subjects
- Carbon Radioisotopes, Cell Line drug effects, HIV Infections prevention & control, Herpes Simplex prevention & control, Humans, Polymers pharmacology, Gels pharmacology, HIV-1 drug effects, Herpesvirus 2, Human drug effects, Sexually Transmitted Diseases prevention & control
- Abstract
Background: Sexually transmitted diseases (STDs) caused by HIV, herpes simplex virus (HSV), and other pathogens are spreading dramatically. The need to develop active products and vehicles to reduce this epidemic is urgent., Goal: The efficacy of a thermoreversible gel formulation as a possible barrier to prevent the transmission of pathogens causing STDs was evaluated., Study Design: This evaluation investigated the ability of the gel formulation to prevent infection of susceptible cells by HIV-1 and HSV-2 in vitro, the diffusion of radiolabeled herpes virus and micelles of polymer through an insertion membrane, and the electron microscopic appearance of herpes virus and gel alone or mixed together., Results: The gel formulation prevents infection of susceptible cells by HIV-1 and HSV-2. It acts as an effective artificial physical barrier against the herpes virus within the first 4 hours of incubation. Herpes virus is coated by the gel or entrapped within micelles of the gel, which could hinder its attachment to target cells and inhibit its infectivity., Conclusion: This thermoreversible gel formulation represents an attractive matrix for the incorporation of microbicides to prevent the spread of STDs.
- Published
- 2001
- Full Text
- View/download PDF
4. Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment.
- Author
-
Bestman-Smith J, Piret J, Désormeaux A, Tremblay MJ, Omar RF, and Bergeron MG
- Subjects
- Cell Membrane physiology, Cells, Cultured, Dose-Response Relationship, Drug, Genes, Viral, HIV-1 physiology, Herpesvirus 1, Human drug effects, Humans, Luciferases metabolism, Sexually Transmitted Diseases prevention & control, Viral Envelope Proteins genetics, Virion physiology, HIV-1 drug effects, Sodium Dodecyl Sulfate pharmacology, Surface-Active Agents pharmacology, Virus Replication drug effects
- Abstract
The microbicidal activity of sodium lauryl sulfate (SLS) against human immunodeficiency virus type 1 (HIV-1) was studied in cultured cells. Pretreatment of HIV-1(NL4-3) with SLS decreased, in a concentration-dependent manner, its infectivity when using 1G5 as target cells. In the absence of a viral pretreatment period or when 1G5 cells were pretreated with SLS, the surfactant-induced inactivation of viral infectivity was less pronounced, especially at concentrations between 375 and 550 microM. SLS had no effect on HIV-1 when the virus was adsorbed to 1G5 cells by a 2-h incubation period. SLS almost completely inhibited the fusion process by decreasing the attachment of HIV-1 to target cells. SLS also inhibited the infectivity of HIV-1-based luciferase reporter viruses pseudotyped with the amphotropic murine leukemia virus envelope (which enters cells in a CD4-, CCR5-, and CXCR4-independent manner), indicating that SLS may inactivate other envelope viruses. In contrast, no effect was seen with vesicular stomatitis virus envelope glycoprotein G (which enters cells through receptor-mediated endocytosis) pretreated with up to 700 microM SLS. SLS also decreased, in a dose-dependent manner, the HIV-1-dependent syncytium formation between 1G5 and J1.1 cells after a 24-h incubation. The reduction of luciferase activity was more pronounced when J1.1 cells (which express HIV-1 proteins on their surface) were pretreated with SLS rather than 1G5 cells. Taken together, our results suggest that SLS could represent a candidate of choice for use in vaginal microbicides to prevent the sexual transmission of HIV and possibly other pathogens causing sexually transmitted diseases.
- Published
- 2001
- Full Text
- View/download PDF
5. Neuraminidase from a bacterial source enhances both HIV-1-mediated syncytium formation and the virus binding/entry process.
- Author
-
Sun J, Barbeau B, Sato S, and Tremblay MJ
- Subjects
- CD4-Positive T-Lymphocytes virology, Coculture Techniques, HIV Envelope Protein gp120 biosynthesis, Humans, Jurkat Cells, N-Acetylneuraminic Acid metabolism, Viral Envelope Proteins metabolism, Virion metabolism, Virus Replication, Arthrobacter enzymology, Giant Cells virology, HIV-1 physiology, Membrane Glycoproteins, Neuraminidase metabolism, Receptors, Virus physiology
- Abstract
Neuraminidases, also termed sialidases, which catalyze the removal of sialic acid residues from various glycoconjugates, have been previously reported to modulate HIV-1 replication. Given that some of the known opportunistic microbes found in patients infected with HIV-1 harbor neuraminidase (NA) activity, we speculated that pathogen-derived NA might be envisaged as an important factor in the pathogenesis of this retroviral infection. In the present study, we have monitored the putative modulation of HIV-1-mediated syncytium formation and virus replication by highly purified bacterial-derived NA from Arthrobacter ureafaciens. Taking advantage of a luciferase-based syncytium quantitative assay, we demonstrate here that the level of HIV-1-mediated syncytium formation is enhanced in the presence of NA and that it necessitates interaction between gp120 and CD4/chemokine coreceptor. By using pseudotyped recombinant luciferase-encoding HIV-1 particles, we found that NA treatment of human CD4-positive target cells (i.e., T lymphoid, monocytoid, and peripheral blood mononuclear cells) significantly augmented single-round infection by T- and macrophage-tropic isolates of HIV-1. The observed increase in HIV-1 infection was linked with an enhancement in the initial steps of the virus replicative cycle as monitored by viral binding and entry assays. Interestingly, NA treatment also enhances infectivity of HIV-1 pseudotypes with envelope glycoprotein from the amphotropic murine leukemia virus or the vesicular stomatitis virus. Taken together, our results provide useful information regarding the possible contribution of microbial agents carrying NA activity to HIV-1 pathogenesis., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
6. Regulation of nuclear factor of activated T cells by phosphotyrosyl-specific phosphatase activity: a positive effect on HIV-1 long terminal repeat-driven transcription and a possible implication of SHP-1.
- Author
-
Fortin JF, Barbeau B, Robichaud GA, Paré ME, Lemieux AM, and Tremblay MJ
- Subjects
- Active Transport, Cell Nucleus, Adult, Cyclosporine pharmacology, Enzyme Inhibitors pharmacology, Gene Expression Regulation drug effects, Gene Expression Regulation physiology, Humans, Immunosuppressive Agents pharmacology, Interleukin-1 genetics, Interleukin-2 pharmacology, Intracellular Signaling Peptides and Proteins, Ionomycin pharmacology, Jurkat Cells drug effects, Jurkat Cells metabolism, Lymphocyte Specific Protein Tyrosine Kinase p56(lck) deficiency, Lymphocyte Specific Protein Tyrosine Kinase p56(lck) physiology, NF-kappa B physiology, NFATC Transcription Factors, Organometallic Compounds pharmacology, Phytohemagglutinins pharmacology, Promoter Regions, Genetic drug effects, Protein Transport, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatases antagonists & inhibitors, Protein-Tyrosine Kinases physiology, Receptors, Antigen, T-Cell physiology, Recombinant Fusion Proteins biosynthesis, Recombinant Proteins pharmacology, Tacrolimus pharmacology, Tetradecanoylphorbol Acetate pharmacology, ZAP-70 Protein-Tyrosine Kinase, DNA-Binding Proteins physiology, HIV Long Terminal Repeat physiology, HIV-1 physiology, Nuclear Proteins, Protein Tyrosine Phosphatases physiology, Transcription Factors physiology, Transcription, Genetic drug effects
- Abstract
Although protein tyrosine phosphatase (PTP) inhibitors used in combination with other stimuli can induce interleukin 2 (IL-2) production in T cells, a direct implication of nuclear factor of activated T cells (NFAT) has not yet been demonstrated. This study reports that exposure of leukemic T cells and human peripheral blood mononuclear cells to bis-peroxovanadium (bpV) PTP inhibitors markedly induce activation and nuclear translocation of NFAT. NFAT activation by bpV was inhibited by the immunosuppressive drugs FK506 and cyclosporin A, as well as by a specific peptide inhibitor of NFAT activation. Mobility shift assays showed specific induction of the NFAT1 member by bpV molecules. The bpV-mediated NFAT activation was observed to be important for the up-regulation of the human immunodeficiency virus 1 (HIV-1) long terminal repeat (LTR) and the IL-2 promoter; NFAT1 was demonstrated to be particularly important in bpV-dependent positive action on HIV-1 LTR transcription. The active participation of p56(lck), ZAP-70, p21(ras), and calcium in the bpV-mediated signaling cascade leading to NFAT activation was confirmed, using deficient cell lines and dominant-negative mutants. Finally, overexpression of wild-type SHP-1 resulted in a greatly diminished activation of NFAT by bpV, suggesting an involvement of SHP-1 in the regulation of NFAT activation. These data were confirmed by constitutive NFAT translocation observed in Jurkat cells stably expressing a dominant-negative version of SHP-1. The study proposes that PTP activity attenuates constitutive kinase activities that otherwise would lead to constant NFAT activation and that this activation is participating in HIV-1 LTR stimulation by PTP inhibition.
- Published
- 2001
- Full Text
- View/download PDF
7. Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.
- Author
-
Genois N, Barbeau B, Olivier M, and Tremblay MJ
- Subjects
- Animals, Anti-HIV Agents isolation & purification, CD4 Antigens biosynthesis, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes virology, Cell Line drug effects, Dose-Response Relationship, Drug, Gene Expression Regulation drug effects, Genes, Reporter, Giant Cells, Glycosphingolipids isolation & purification, HIV-1 physiology, Humans, Jurkat Cells drug effects, Jurkat Cells virology, Luciferases analysis, Lymphocyte Function-Associated Antigen-1 biosynthesis, Membrane Fusion drug effects, Receptors, CXCR4 biosynthesis, Signal Transduction drug effects, Transfection, Anti-HIV Agents pharmacology, Cytopathogenic Effect, Viral drug effects, Glycosphingolipids pharmacology, HIV-1 drug effects, Leishmania donovani chemistry, Virus Replication drug effects
- Abstract
Previous findings have indicated that the major surface molecule of Leishmania, lipophosphoglycan (LPG), could abrogate HIV-1-induced syncytium formation and virus replication. In the present work, we were interested in characterizing this inhibitory process. Data from a new luciferase-based semiquantitative assay for syncytium formation, relying on the coincubation of a T-cell line containing an HIV-1 LTR-driven luciferase construct with a cell line chronically infected with HIV-1, confirmed that LPG was indeed a strong inhibitor of HIV-1-dependent syncytium formation and that this inhibition was dose-dependent. As determined by flow cytometric analyses, this inhibition was not apparently due to downregulation of CD4, CXCR4 or LFA-1, three distinct surface glycoproteins known to be important in HIV-1 mediated syncytium formation. Furthermore, LPG did not seem to affect signal transduction pathways in T cells as judged by measurement of HIV-1 LTR-driven reporter gene activity upon treatment with different stimuli. However, pretreatment of either of the cell lines used in the assay with LPG led to a significant decrease of virus-mediated syncytium formation, which was further accentuated when both cell lines were pretreated. LPG inhibition of HIV-1 replication was next assessed. When measuring either infection with luciferase-encoding recombinant HIV-1 particles or multinucleated giant cell formation following an acute virus infection, we again observed that LPG was efficient at blocking HIV-1 replication. Specific assays probing different steps of viral entry demonstrated that attachment was not hindered by LPG but that viral entry was modulated, suggesting that LPG targets a postbinding step. Hence, incorporation of LPG into a target cell membrane could influence its fluidity and diminish both the virus-cell and cell-to-cell fusion processes initiated by HIV-1.
- Published
- 2001
- Full Text
- View/download PDF
8. Attachment of human immunodeficiency virus-1 (HIV-1) particles bearing host-encoded B7-2 proteins leads to nuclear factor-kappa B- and nuclear factor of activated T cells-dependent activation of HIV-1 long terminal repeat transcription.
- Author
-
Bounou S, Dumais N, and Tremblay MJ
- Subjects
- B7-2 Antigen, CD28 Antigens physiology, Enhancer Elements, Genetic, HIV-1 physiology, Humans, Jurkat Cells, NF-KappaB Inhibitor alpha, NFATC Transcription Factors, Receptor-CD3 Complex, Antigen, T-Cell physiology, Antigens, CD physiology, DNA-Binding Proteins physiology, HIV Long Terminal Repeat, HIV-1 genetics, I-kappa B Proteins, Membrane Glycoproteins physiology, NF-kappa B physiology, Nuclear Proteins, Transcription Factors physiology, Transcriptional Activation, Virion physiology
- Abstract
Previous studies have shown that human immunodeficiency virus type-1 (HIV-1) can incorporate several surface proteins of host origin. Recent findings indicate that host-encoded cell surface constituents retain their functionality when found embedded into the viral envelope. The primary objective of the current study was to define whether interaction between some specific virion-bound host proteins with their natural cognate ligands present on target cells could mediate intracellular signaling cascade(s). For this purpose, we have generated a whole series of isogenic virus stocks (NL4-3 backbone) bearing or not bearing on their surface foreign CD28, CD54 (ICAM-1), CD80 (B7-1) or CD86 (B7-2) proteins. Our results indicate that incubation of human T lymphoid cells with virions bearing host-derived B7-2 proteins and anti-CD3 antibody can potently activate HIV-1 long terminal repeat-driven gene expression. This up-regulating effect necessitates the involvement of nuclear factor-kappa B (NF-kappa B) and nuclear factor of activated T cells (NFAT) as revealed by the use of vectors coding for dominant negative versions of both transcription factors (i.e. I kappa B alpha S32A/36A and dnNFAT) and band shift assays. The increase of NF-kappa B activity was abolished when infection with B7-2-bearing HIV-1 particles was performed in the presence of the fusion protein CTLA-4 Ig suggesting that the interaction between virally embedded B7-2 and CD28 on the target cell is responsible for the observed NF-kappa B induction. The findings presented here provide the first demonstration that host-encoded proteins acquired by HIV-1 can mediate signal transduction events.
- Published
- 2001
- Full Text
- View/download PDF
9. Mono Mac 1: a new in vitro model system to study HIV-1 infection in human cells of the mononuclear phagocyte series.
- Author
-
Genois N, Robichaud GA, and Tremblay MJ
- Subjects
- CD4 Antigens analysis, Cell Differentiation, Cytopathogenic Effect, Viral, Flow Cytometry, Humans, Lipopolysaccharides pharmacology, NF-kappa B metabolism, Polymerase Chain Reaction, Receptors, CCR3, Receptors, CCR5 analysis, Receptors, CXCR4 analysis, Receptors, Chemokine analysis, Terminology as Topic, Tetradecanoylphorbol Acetate pharmacology, HIV-1 physiology, Monocytes virology, Tumor Cells, Cultured virology, Virus Cultivation, Virus Replication
- Abstract
Throughout the years, most researchers have used continuous cell lines as in vitro models to evaluate the immunopathogenesis of human immunodeficiency virus type-1 (HIV-1) infection. Unfortunately, the most commonly used monocytoid malignant cells have not been shown to adequately mimic primary human monocyte-derived macrophages, at least with respect to HIV-1 infection. The Mono Mac 1 cell line has been defined as a model system for studying biochemical, immunological, and genetic functions of human cells of the monocyte/macrophage lineage. In this study, we have investigated whether Mono Mac 1 represents an in vitro culture system for HIV-1 infection. Flow cytometric analyses revealed that Mono Mac 1 are positive for the HIV-1 primary receptor (CD4), as well as for the coreceptors (CXCR4, CCR5, and CCR3). Infectivity experiments conducted with recombinant luciferase-encoding and fully infectious viruses demonstrated that Mono Mac 1 can support a highly productive infection with both macrophage- and dual-tropic isolates of HIV-1. Furthermore, differentiation of such cells led to a marked increase in virus production. Data from semiquantitative polymerase chain reaction analysis and mobility shift assays indicated that enhanced virus production in differentiated Mono Mac 1 cells was most likely related to an increase in nuclear translocation of NF-kappaB. Mono Mac 1 can thus be considered as a human monocytoid cell line representing a proper in vitro system for studying the complex interactions between HIV-1 and cells of the monocyte/macrophage lineage.
- Published
- 2000
10. Targeting cell-free HIV and virally-infected cells with anti-HLA-DR immunoliposomes containing amphotericin B.
- Author
-
Bestman-Smith J, Désormeaux A, Tremblay MJ, and Bergeron MG
- Subjects
- Antibodies pharmacology, Antibody Specificity, Cell Line, Drug Delivery Systems, HIV-1 immunology, HIV-1 pathogenicity, Humans, Immunoglobulin Fab Fragments immunology, Jurkat Cells, Liposomes administration & dosage, Amphotericin B pharmacology, Antibodies immunology, HIV Infections virology, HIV-1 drug effects, HLA-DR Antigens immunology, Liposomes immunology
- Abstract
Objective: To evaluate the ability of liposomes bearing anti-HLA-DR Fab' fragments (immunoliposomes) and containing amphotericin B (AmB) to target and neutralize cell-free HIV-1 particles and virally-infected cells., Methods: The effect of AmB on the attachment and fusion of HIV-1(NL4-3) to Jurkat E6.1 cells has been evaluated using a p24 enzymatic assay. The ability of AmB to inhibit HIV-1-based luciferase reporter viruses pseudotyped with HXB2, AML-V and VSV-G envelopes has been evaluated in Jurkat E6.1 cells. The efficacy of free and immunoliposomal AmB to inhibit cell-free HIV, that have incorporated or not HLA-DR molecules, has been evaluated in HLA-DR/negative (NEG) 1G5 T cells and HLA-DR/positive (POS) Mono Mac 1 cells., Results: AmB inhibited HIV infectivity independently of the nature of viral envelope proteins. Pretreatment of HIV with AmB had no major effect on viral attachment and fusion process to Jurkat E6.1 cells. Immunoliposomal AmB (0.5 microg/ml) led to a 77% inhibition of replication of HLA-DR/POS HIV-1 with no cell toxicity, whereas free AmB had no significant antiviral activity at this concentration. A complete inhibition of viral replication was observed following incubation of viruses with immunoliposomal AmB (2.5 microg/ml). Anti-HLA-DR immunoliposomes containing AmB had no effect on the infectivity of HLA-DR/NEG HIV-1 particles in HLA-DR/NEG T lymphoid cells but completely inhibited replication of viruses in an HLA-DR/POS monocytic cell line., Conclusion: The incorporation of neutralizing agents in anti-HLA-DR immunoliposomes could represent a novel therapeutic strategy to specifically target cell-free HIV particles and virally-infected cells to treat HIV infection more efficiently.
- Published
- 2000
- Full Text
- View/download PDF
11. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1.
- Author
-
Bestman-Smith J, Gourde P, Désormeaux A, Tremblay MJ, and Bergeron MG
- Subjects
- Animals, Antibodies immunology, Carbocyanines chemistry, Female, Flow Cytometry, Fluorescent Dyes, Immunoglobulin Fab Fragments immunology, In Vitro Techniques, Liposomes analysis, Liposomes chemistry, Lymph Nodes immunology, Lymphoid Tissue drug effects, Mice, Mice, Inbred C3H, Microscopy, Fluorescence, Polyethylene Glycols chemistry, Spleen immunology, Tissue Distribution, Antibodies administration & dosage, Drug Delivery Systems, HIV-1, HLA-DR Antigens immunology, Liposomes immunology, Lymphoid Tissue immunology
- Abstract
The ability of liposomes bearing anti-HLA-DR Fab' fragments at the end termini of polyethyleneglycol chains (sterically stabilized immunoliposomes) to target HLA-DR expressing cells and increase the accumulation of liposomes into lymphoid organs has been evaluated and compared to that of conventional liposomes, sterically stabilized liposomes and conventional immunoliposomes after a single subcutaneous injection to mice. The accumulation of sterically stabilized liposomes in lymph nodes was higher than that of conventional liposomes. Sterically stabilized immunoliposomes accumulated much better than conventional immunoliposomes in all tissues indicating that the presence of PEG has an important effect on the uptake of immunoliposomes by the lymphatic system. Fluorescence microscopy studies showed that sterically stabilized liposomes are mainly localized in macrophage-rich areas such as the subcapsular region of lymph nodes and in the red pulp and marginal zone of the spleen. In contrast, sterically stabilized immunoliposomes mostly accumulated in the cortex in which follicles are located and in the white pulp of the spleen. As the human HLA-DR determinant of the major histocompatibility complex class II is expressed on activated CD4+ T lymphocytes and antigen presenting cells such as monocyte/macrophages and dendritic cells, known as the cellular reservoirs of HIV-1, liposomes bearing anti-HLA-DR antibodies constitute an attractive approach to concentrate drugs in HIV-1 reservoirs and improve their therapeutic effect.
- Published
- 2000
- Full Text
- View/download PDF
12. Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization.
- Author
-
Fortin JF, Cantin R, Bergeron MG, and Tremblay MJ
- Subjects
- Adult, Antibodies, Monoclonal metabolism, Cell Line, Genes, Reporter immunology, HIV-1 metabolism, Humans, Immune Sera immunology, Intercellular Adhesion Molecule-1 immunology, Jurkat Cells, Luciferases genetics, Lymphocyte Function-Associated Antigen-1 immunology, Macrophages immunology, Macrophages virology, Middle Aged, Neutralization Tests, Sensitivity and Specificity, Tumor Cells, Cultured, HIV-1 immunology, HIV-1 isolation & purification, Intercellular Adhesion Molecule-1 metabolism, Lymphocyte Function-Associated Antigen-1 metabolism, Virion immunology, Virion metabolism
- Abstract
The oligomeric nature of the viral envelope proteins has been partly held responsible for the observed differences in neutralization sensitivity between primary and laboratory-adapted strains of human immunodeficiency virus type 1 (HIV-1). However, recent evidence suggests that host factors can also modify the sensitivity of HIV-1 particles to neutralization. Having previously demonstrated that the acquisition of host-encoded intercellular adhesion molecule (ICAM)-1 proteins by newly formed viruses has a functional significance for the life cycle of HIV-1, we investigated whether the acquisition of host-derived ICAM-1 by HIV-1 could affect the virus sensitivity to neutralization. In this study, we have first shown that the physical presence of host cell membrane ICAM-1 on HIV-1 was not modifying virus sensitivity to neutralization by either two different anti-gp120 monoclonal antibodies (0.5beta and 4.8D) or soluble CD4. However, the ability of the F105 anti-gp120 monoclonal antibody (specific for the CD4-binding site) to neutralize ICAM-1-bearing virions was diminished when target cells were pretreated with an lymphocyte function-associated antigen-1 (LFA-1)-activating antibody. Interestingly, ICAM-1/POS progeny viruses were found to be slightly more resistant to neutralization by individual human sera in target cells expressing a low-affinity form of LFA-1 than viruses devoid of host-encoded ICAM-1 proteins. This resistance was markedly enhanced when target cells expressed an activated LFA-1 form on their surface. These results suggest that the interaction between virally embedded host ICAM-1 and target cell surface LFA-1 should be considered a factor modulating neutralization sensitivity of HIV-1 by human sera from HIV-1-infected individuals., (Copyright 2000 Academic Press.)
- Published
- 2000
- Full Text
- View/download PDF
13. Role of the leukocyte function antigen-1 conformational state in the process of human immunodeficiency virus type 1-mediated syncytium formation and virus infection.
- Author
-
Fortin JF, Barbeau B, Hedman H, Lundgren E, and Tremblay MJ
- Subjects
- Cell Line, Humans, Intercellular Adhesion Molecule-1 metabolism, Protein Conformation, Receptors, CXCR4 biosynthesis, Receptors, CXCR4 metabolism, Structure-Activity Relationship, Tumor Cells, Cultured, Cell Transformation, Viral, Giant Cells virology, HIV Infections virology, HIV-1 pathogenicity, Lymphocyte Function-Associated Antigen-1 physiology
- Abstract
Human immunodeficiency virus type 1 (HIV-1)-mediated syncytium formation is recognized as being highly dependent on intercellular adhesion molecule (ICAM)-1-leukocyte function-associated molecule 1 (LFA)-1 interaction, whereas the process of infection with cell-free virions is independent of such complementary interaction. Our group has recently demonstrated that an antibody-mediated induction of the high affinity state of LFA-1 for ICAM-1 renders target T cells more prone to HIV-1-dependent syncytium formation and infection by ICAM-1-bearing virions. To further substantiate these results, we made use of mutant cell lines expressing LFA-1 in either a low (parental HPB-ALL and HAmut) or a high affinity state for ICAM-1 (HAP4) and compared syncytium formation and virus infection. Cells expressing the activated form of LFA-1 were found to be more susceptible to HIV-1-induced syncytium formation and to infection by ICAM-1-bearing HIV-1 particles. The observed increase was solely due to the LFA-1 activation state because it was abrogated by anti-LFA-1 or anti-ICAM-1 antibodies and not due to variations in surface expression of LFA-1, CD4, or the chemokine coreceptor CXCR4. However, a linear relation was seen between the level of CXCR4 surface expression and susceptibility to syncytium formation/virus infection when ICAM-1-LFA-1 interaction was either absent (i.e., infection with ICAM-1-negative virions) or abrogated (treatment with anti-LFA-1 or anti-ICAM-1 antibodies). These results emphasize the important role of the LFA-1 activation state with respect to virus-induced syncytium formation and HIV-1 infection., (Copyright 1999 Academic Press.)
- Published
- 1999
- Full Text
- View/download PDF
14. Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity.
- Author
-
Paquette JS, Fortin JF, Blanchard L, and Tremblay MJ
- Subjects
- Cell Line, Cell Membrane metabolism, HIV Infections etiology, HIV Infections immunology, HIV Infections virology, HIV-1 physiology, Humans, Intercellular Adhesion Molecule-1 genetics, Jurkat Cells, Lymphocyte Activation, Lymphocyte Function-Associated Antigen-1 chemistry, Lymphocyte Function-Associated Antigen-1 metabolism, Macrophage Activation, Macrophages immunology, Macrophages virology, Protein Conformation, Signal Transduction, T-Lymphocytes immunology, T-Lymphocytes virology, Transfection, Virulence, Virus Replication physiology, HIV-1 pathogenicity, Intercellular Adhesion Molecule-1 metabolism
- Abstract
Using virions harvested from 293T cells stably expressing either low or high levels of surface ICAM-1, we determined that the number of virus-embedded host ICAM-1 proteins is positively influenced by the expression level of ICAM-1 on virus producer cells. Moreover, the increase in virion-bound host cell membrane ICAM-1 led to a concomitant enhancement of virus infectivity when a T-cell-tropic strain of human immunodeficiency virus type 1 (HIV-1) was used. The phenomenon was also seen when primary human cells were infected with virions pseudotyped with the envelope protein from a macrophage-tropic HIV-1 isolate, thus ruling out any envelope-specific effect. We also observed that target cells treated with NKI-L16, an anti-LFA-1 antibody known to increase the affinity of LFA-1 for ICAM-1, were markedly more susceptible to infection with HIV-1 particles bearing on their surfaces large numbers of host-derived ICAM-1 proteins. Given that cellular activation of leukocytes is known to modify the conformational state of LFA-1 and induce ICAM-1 surface expression, it is tempting to speculate that activation of virus-infected cells will lead to the production of HIV-1 particles bearing more host ICAM-1 on their surfaces and that such progeny virions will preferentially infect and replicate more efficiently in activated cells which are prevalent in lymphoid organs.
- Published
- 1998
- Full Text
- View/download PDF
15. Prostaglandin E2 Up-regulates HIV-1 long terminal repeat-driven gene activity in T cells via NF-kappaB-dependent and -independent signaling pathways.
- Author
-
Dumais N, Barbeau B, Olivier M, and Tremblay MJ
- Subjects
- Calcium metabolism, Cell Lineage, Cyclic AMP metabolism, Cyclic AMP-Dependent Protein Kinases metabolism, Genes, Reporter, Humans, Jurkat Cells, Luciferases biosynthesis, Models, Genetic, Proviruses, Receptors, Prostaglandin E metabolism, Receptors, Prostaglandin E, EP4 Subtype, Second Messenger Systems, Transcription, Genetic, Virus Latency, Dinoprostone pharmacology, HIV Long Terminal Repeat, HIV-1 genetics, NF-kappa B metabolism, T-Lymphocytes virology
- Abstract
Replication of human immunodeficiency virus type-1 (HIV-1) is highly dependent on the state of activation of the infected cells and is modulated by interactions between viral and host cellular factors. Prostaglandin E2 (PGE2), a pleiotropic immunomodulatory molecule, is observed at elevated levels during HIV-1 infection as well as during the course of other pathogenic infections. In 1G5, a Jurkat-derived T cell line stably transfected with a luciferase gene driven by HIV-1 long terminal repeat (LTR), we found that PGE2 markedly enhanced HIV-1 LTR-mediated reporter gene activity. Experiments have been conducted to identify second messengers involved in this PGE2-dependent up-regulating effect on the regulatory element of HIV-1. In this study, we present evidence indicating that signal transduction pathways induced by PGE2 necessitate the participation of cyclic AMP, protein kinase A, and Ca2+. Experiments conducted with different HIV-1 LTR-based vectors suggested that PGE2-mediated activation effect on HIV-1 transcription was transduced via both NF-kappaB-dependent and -independent signaling pathways. The involvement of NF-kappaB in the PGE2-dependent activating effect on HIV-1 transcription was further confirmed using a kappaB-regulated luciferase encoding vector and by electrophoretic mobility shift assays. Results from Northern blot and flow cytometric analyses, as well as the use of a selective antagonist indicated that PGE2 modulation of HIV-1 LTR-driven reporter gene activity in studied T lymphoid cells is transduced via the EP4 receptor subtype. These results suggest that secretion of PGE2 by macrophages in response to infection or inflammatory activators could induce signaling events resulting in activation of proviral DNA present into T cells latently infected with HIV-1.
- Published
- 1998
- Full Text
- View/download PDF
16. Modulation of human immunodeficiency virus type 1-induced syncytium formation by the conformational state of LFA-1 determined by a new luciferase-based syncytium quantitative assay.
- Author
-
Barbeau B, Fortin JF, Genois N, and Tremblay MJ
- Subjects
- Antibodies immunology, Antigens, CD metabolism, CD4 Antigens metabolism, Cell Adhesion Molecules metabolism, Giant Cells, HeLa Cells, Humans, Intercellular Adhesion Molecule-1 metabolism, Jurkat Cells, Leukocytes, Mononuclear, Lymphocyte Function-Associated Antigen-1 immunology, Receptors, CXCR4 metabolism, Tumor Cells, Cultured, HIV-1 physiology, Luciferases metabolism, Lymphocyte Function-Associated Antigen-1 metabolism
- Abstract
The ICAM-1/LFA-1 interaction has been clearly demonstrated to play an active role in syncytium formation induced by human immunodeficiency virus type 1 (HIV-1). Since it is known that a high-affinity state of LFA-1 for ICAM-1 can be induced through conformational change, such a high-affinity state may also contribute to the process of syncytium formation. In this study, we have investigated the involvement of the conformational status of LFA-1 in HIV-1-dependent syncytium formation by using the anti-LFA-1 antibody NKI-L16, which is known to activate the high-affinity state. Initial visual observations by light microscopy indeed suggested that the addition of the NKI-L16 antibody led to bigger and more numerous syncytia when different cell lines were tested. To further analyze this NKI-L16-dependent increment of syncytium formation in a quantitative assay, a new luciferase-based assay was developed by using a T-cell line containing an HIV-1 long terminal repeat (LTR)-driven luciferase construct (1G5) in coincubation with an HIV-1-positive cell line (J1.1). Upon fusion, the viral Tat protein could diffuse to the 1G5 cells, leading to a transcriptional increase of the HIV-1 LTR-driven luciferase gene. Initial evaluation of this assay showed a good correlation between the level of syncytium formation determined by microscopic observation and the level of measured luciferase activity. In addition, this assay showed a greater induction of enzymatic activity correlating with syncytium formation in comparison to a similar incubation with the HeLa-CD4-LTR-beta-gal indicator cell line. By using this test, NKI-L16 treatment of 1G5/J1.1 cells led to a three- to sevenfold increase in HIV-1 LTR-driven luciferase activity. The syncytium-dependent luciferase activity in NKI-L16-treated cells could be blocked by classical syncytium inhibitors such as soluble CD4, anti-CD4, and anti-gp120 antibodies. Inhibition could also be observed with specific blocking agents for the chemokine receptor CXCR4, as well as with soluble ICAM-1, anti-LFA-1, anti-ICAM-1, and anti-ICAM-2 blocking antibodies, indicating the requirement for the LFA-1/ICAM interaction. Treatment of peripheral blood mononuclear cells with NKI-L16 resulted in a higher level of syncytium formation in the presence of the cell line J1.1. Conversely, when PBMCs were infected with two different syncytium-inducing HIV-1 primary isolates, coincubation with NKI-L16-pretreated 1G5 cells led to higher levels of luciferase activity for both virus isolates. Our results therefore show for the first time a direct role for the LFA-1 high-affinity state in virus-mediated syncytium formation. Based on the demonstration that an increase in ICAM-1 binding is induced by T-cell activation, these data suggest an in vivo involvement of the high-affinity state of LFA-1 in HIV-1-induced syncytium formation. Moreover, syncytia might preferentially occur in lymph nodes, since this microenvironment harbors a high proportion of activated T cells.
- Published
- 1998
- Full Text
- View/download PDF
17. The acquisition of host-encoded proteins by nascent HIV-1.
- Author
-
Tremblay MJ, Fortin JF, and Cantin R
- Subjects
- Animals, Antigens, CD metabolism, HIV Antibodies biosynthesis, HIV Infections immunology, HIV-1 physiology, Histocompatibility Antigens metabolism, Humans, Virus Replication, HIV Infections virology, HIV-1 metabolism, Proteins metabolism
- Published
- 1998
- Full Text
- View/download PDF
18. Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate.
- Author
-
Thivierge M, Le Gouill C, Tremblay MJ, Stanková J, and Rola-Pleszczynski M
- Subjects
- Dinoprostone therapeutic use, Down-Regulation, Gene Expression Regulation, Viral drug effects, HIV Infections virology, Humans, Oxytocics therapeutic use, Signal Transduction drug effects, Virus Replication, Cyclic AMP physiology, Dinoprostone pharmacology, HIV Infections drug therapy, HIV-1 physiology, Macrophages physiology, Macrophages virology, Oxytocics pharmacology, Receptors, CCR5 physiology
- Abstract
The chemokine receptor CCR5 can function as a coreceptor for human immunodeficiency virus-1 (HIV-1) entry into CD4(+) T cells and macrophages, especially during the early stages of HIV-1 infection. The regulation of CCR5 expression may affect not only leukocyte migration, but also infectivity by HIV-1 and, therefore, acquired immunodeficiency syndrome (AIDS) pathogenesis. We report here that agents which increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) rapidly downregulate CCR5 gene expression, with consequent loss of CCR5 expression and function in monocytes/macrophages. Chemotaxis and intracellular Ca2+ mobilization in monocytes pretreated with prostaglandin E2 or dibutyryl-cAMP for 24 hours were significantly reduced in response to the CCR5 ligand, MIP-1beta. Moreover, HIV-1 entry into monocyte-derived macrophages pretreated with dibutyryl-cAMP or prostaglandin E2 was markedly decreased. Our findings suggest that resistance to HIV-1 can be induced by agents which increase cellular levels of cAMP and that this may suggest additional therapeutic strategies to limit infection by HIV-1.
- Published
- 1998
19. Mycobacterium tuberculosis mannose-capped lipoarabinomannan can induce NF-kappaB-dependent activation of human immunodeficiency virus type 1 long terminal repeat in T cells.
- Author
-
Bernier R, Barbeau B, Olivier M, and Tremblay MJ
- Subjects
- Binding Sites, Cyclic AMP-Dependent Protein Kinases metabolism, Humans, Jurkat Cells, Lipopolysaccharides pharmacology, Mannose, Protein Kinase C metabolism, Protein-Tyrosine Kinases metabolism, Transcription, Genetic, Tumor Necrosis Factor-alpha metabolism, Up-Regulation, Gene Expression Regulation, Viral, HIV Long Terminal Repeat, HIV-1 genetics, Lipopolysaccharides metabolism, Mycobacterium tuberculosis metabolism, NF-kappa B metabolism, T-Lymphocytes virology
- Abstract
Tuberculosis has emerged as an epidemic, extended by the large number of individuals infected with human immunodeficiency virus type 1 (HIV-1). The major goal of this study was to determine whether the mycobacterial cell wall component mannose-capped lipoarabinomannan (ManLAM) of Mycobacterium tuberculosis (M. tuberculosis) could activate transcription of HIV-1 in T cells with the use of an in vitro cell culture system. These experiments are of prime importance considering that CD4-expressing T lymphocytes represent the major virus reservoir in the peripheral blood of infected individuals. Using the 1G5 cell line harbouring the luciferase reporter gene under the control of the HIV-1 LTR, it was first found that culture protein filtrates (CFP) from M. tuberculosis or purified ManLAM could activate HIV-1 LTR-dependent gene expression unlike similarly prepared CFP extracts devoid of ManLAM. The implication of protein tyrosine kinase(s), protein kinase A and/or protein kinase C was highlighted by the abrogation of the ManLAM-mediated activation of HIV-1 LTR-driven gene expression using herbimycin A and H7. It was also determined, using electrophoresis mobility shift assays, that M. tuberculosis ManLAM led to the nuclear translocation of the transcription factor NF-kappaB. M. tuberculosis ManLAM resulted in clear induction of the luciferase gene placed under the control of the wild-type, but not the kappaB-mutated, HIV-1 LTR region. Finally, the ManLAM-mediated activation of HIV-1 LTR transcription was found to be independent of the autocrine or paracrine action of endogenous TNF-alpha. The results suggest that M. tuberculosis can upregulate HIV-1 expression in T cells and could thus have the potential to influence the pathogenesis of HIV-1 infection.
- Published
- 1998
- Full Text
- View/download PDF
20. The lipophosphoglycan of Leishmania donovani up-regulates HIV-1 transcription in T cells through the nuclear factor-kappaB elements.
- Author
-
Bernier R, Barbeau B, Tremblay MJ, and Olivier M
- Subjects
- Animals, Calcium metabolism, Humans, Jurkat Cells, Up-Regulation, Glycosphingolipids pharmacology, HIV Long Terminal Repeat, HIV-1 genetics, Leishmania donovani physiology, NF-kappa B physiology, Transcription, Genetic
- Abstract
We have recently demonstrated that the parasite Leishmania donovani and its surface molecule, lipophosphoglycan (LPG), can activate HIV-1 replication in monocytoid cells. Our present interest was to determine whether LPG could also up-regulate HIV-1 transcription in T cells. Using a CD4-positive human lymphoid T cell line (1G5) containing a stably integrated HIV-1 long terminal repeat (LTR)-luciferase construct, we found that LPG is a potent inducer of HIV-1 LTR activity. Treatment of 1G5 cells with signaling antagonists revealed that protein tyrosine kinase- and protein kinase A-dependent pathways were actively participating in the LPG-induced enhancement of HIV-1 LTR-driven activity. Transfection of Jurkat E6.1 cells with plasmids containing wild-type and nuclear factor-kappaB (NF-kappaB)-mutated HIV-1 LTR-luciferase constructs has suggested a role for NF-kappaB binding sites in the LPG-mediated induction of HIV-1 LTR activity. An LPG-induced binding factor specific to the NF-kappaB consensus sequences could be observed using electrophoretic mobility shift assay. Finally, transfection experiments performed with a vector containing HIV-1 kappaB binding sites only showed similar LPG-mediated induction, which was abrogated by sodium salicylate, a known NF-kappaB inhibitor. We thus demonstrate that the LPG-mediated induction of HIV-1 LTR activity in T cells involves several second messengers culminating in activation of HIV-1 LTR-driven transcription via NF-kappaB-binding consensus sequences. In conclusion, these results reinforce the idea that L. donovani is a putative cofactor in HIV-1 pathogenesis.
- Published
- 1998
21. T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1.
- Author
-
Fortin JF, Cantin R, and Tremblay MJ
- Subjects
- Antibodies metabolism, Cell Line, Cells, Cultured, Humans, Jurkat Cells, Leukocytes, Mononuclear cytology, Receptors, Antigen, T-Cell immunology, Receptors, Antigen, T-Cell metabolism, T-Lymphocytes cytology, Virion, HIV-1 metabolism, Intercellular Adhesion Molecule-1 metabolism, Lymphocyte Function-Associated Antigen-1 metabolism, T-Lymphocytes metabolism, T-Lymphocytes virology
- Abstract
The incorporation of host-derived proteins in nascent human immunodeficiency virus type 1 (HIV-1) particles is a well-established phenomenon. We recently demonstrated that the physical presence of host-encoded ICAM-1 glycoproteins on HIV-1 leads to a significant increase in virus infectivity in an ICAM-1/LFA-1-dependent fashion (J.-F. Fortin, R. Cantin, G. Lamontagne, and M. Tremblay, J. Virol. 71:3588-3596, 1997). We show here that conversion of LFA-1 to high affinity for ICAM-1 with the use of anti-LFA-1 antibodies (clones NKI-L16 and MEM83) markedly enhances the susceptibility of different target T-lymphoid cell lines, as well as of primary peripheral blood mononuclear cells, to infection by ICAM-1-bearing HIV-1 particles (6- to 95-fold). It is known that T-cell receptor (TCR) cross-linking induces a transient increase in LFA-1 affinity for ICAM-1. Treatment of peripheral blood mononuclear cells with anti-TCR antibodies (clone OKT3) resulted in a transient increase in susceptibility to infection by ICAM-1-positive virions that parallels the previously reported kinetics of the LFA-1/ICAM-1 adhesion mechanism. Our results led us to postulate that the strong interaction taking place between virally incorporated ICAM-1 and cell surface-activated LFA-1 markedly enhances the efficiency of virus binding and entry, thus favoring greater infection by ICAM-1-bearing HIV-1 particles. In view of the knowledge that primary HIV-1 isolates harbor host-derived ICAM-1 on their surfaces, these results provide new information about the role of host-derived ICAM-1 in the life cycle of HIV-1 and how it could positively modulate the dynamics of the viral infection, mainly in cellular compartments, such as the lymphoid tissues, where the level of cellular activation is high and where the probability of encountering a T cell expressing the activated LFA-1 form is also elevated.
- Published
- 1998
- Full Text
- View/download PDF
22. The acquisition of host-derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human T-lymphoid cells.
- Author
-
Cantin R, Fortin JF, Lamontagne G, and Tremblay M
- Subjects
- B-Lymphocytes virology, Burkitt Lymphoma immunology, Burkitt Lymphoma pathology, CD4 Antigens genetics, CD4 Antigens immunology, Disease Susceptibility, Genes, MHC Class II, HIV-1 chemistry, HIV-1 physiology, HLA-D Antigens genetics, Humans, Recombinant Fusion Proteins immunology, Transfection, Tumor Cells, Cultured, Virion chemistry, Virus Replication, HIV-1 immunology, HLA-D Antigens immunology, Membrane Glycoproteins immunology, T-Lymphocytes virology, Virion immunology
- Abstract
Infection by human immunodeficiency virus type 1 (HIV-1) results in a progressive depletion of CD4+ T lymphocytes, leading to fatal immunodeficiency. The mechanisms causing the marked loss of CD4+ T lymphocytes are incompletely understood. However, several lines of evidence indicate that direct cytopathology mediated by HIV-1 is a key element in such CD4+ T-cell depletion. In this study, we investigated whether the previously reported incorporation of host-derived major histocompatibility class II glycoproteins (MHC-II) on HIV-1 can alter its replicative capacity. To achieve this goal, virus stocks were produced in parental MHC-II-expressing RAJI cells and in MHC-II-negative RAJI mutants (RM3), both of which have been stably transfected with human CD4 cDNA to allow productive infection with HIV-1. An enhancement of the rate/efficiency of virus entry was seen after infection with normalized amounts of virions carrying host-derived MHC-II on their surface as compared with inoculation with virions devoid of cellular MHC-II. Data from time-course and infectivity experiments showed that the kinetics of infection were more rapid for virions bearing host-derived MHC-II glycoproteins than for MHC-II-free HIV-1 particles. These results suggest that virally embedded cellular MHC-II glycoproteins are functional and can have a positive effect on early events in the virus replicative cycle. Therefore, we show that the acquisition of cellular MHC-II glycoproteins by HIV-1 can modify its biologic properties and might, consequently, influence the pathogenesis of this retroviral disease.
- Published
- 1997
23. Activation of HIV-1 long terminal repeat transcription and virus replication via NF-kappaB-dependent and -independent pathways by potent phosphotyrosine phosphatase inhibitors, the peroxovanadium compounds.
- Author
-
Barbeau B, Bernier R, Dumais N, Briand G, Olivier M, Faure R, Posner BI, and Tremblay M
- Subjects
- Cell Line, Gene Expression Regulation, Viral drug effects, Humans, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatases physiology, Virus Replication drug effects, HIV Infections virology, HIV Long Terminal Repeat genetics, HIV-1 physiology, NF-kappa B genetics, Protein Tyrosine Phosphatases antagonists & inhibitors, Vanadium Compounds pharmacology, Virus Replication genetics
- Abstract
Replication of human immunodeficiency virus type 1 (HIV-1) is increased by different cytokines and T cell activators, also known to modulate tyrosine phosphorylation levels. A novel class of protein tyrosine phosphatase (PTP) inhibitors, peroxovanadium (pV) compounds, were tested for a putative effect on HIV-1 long terminal repeat (LTR) activity. We found that these PTP inhibitors markedly enhanced HIV-1 LTR activity in 1G5 cells, a stably transfected cell line that harbors an HIV-1 LTR-driven luciferase construct. A direct correlation between the extent of tyrosine phosphorylation and the level of HIV-1 LTR inducibility was seen after treatment with three different pV compounds. Transient transfection experiments were carried out in several T cell lines, and after addition of pV, a marked increase in HIV-1 LTR activity was measured. Monocytoid cells were tested using U937-derived cell lines and were also found to be sensitive to the pV-mediated potentiating effect on HIV-1 LTR activity. A significant reduction of the pV-mediated increase in HIV-1 LTR activity was seen in cells transiently transfected with an HIV-1 LTR-driven luciferase construct bearing a mutation in both NF-kappaB binding sites although detectable levels of induction remained. Electrophoretic mobility shift assays allowed the identification of the nuclear translocation of the NF-kappaB p50.p65 heterodimer complex induced by pV compounds. A dominant negative version of the repressor IkappaBalpha mutated on serines 32 and 36 impeded pV-induced NF-kappaB-dependent luciferase activity. Western blot analysis showed a clear diminution in the protein level of IkappaBalpha starting 30 min after pV treatment of Jurkat E6.1 cells which is indicative of its degradation. On the other hand, no increase in tyrosine phosphorylation was observed on IkappaBalpha itself. Finally, we tested the PTP inhibitors on four cell lines latently infected with HIV-1 and showed a consistent pV-mediated increase in virion production. Thus, our studies suggest that pV-mediated activation of HIV-1 LTR activity is controlled by the nuclear translocation of the NF-kappaB transcription factor, which is mediated by IkappaBalpha serine phosphorylation and degradation, but also by a still undefined NF-kappaB-independent pathway.
- Published
- 1997
- Full Text
- View/download PDF
24. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity.
- Author
-
Fortin JF, Cantin R, Lamontagne G, and Tremblay M
- Subjects
- Cell Line, HIV Long Terminal Repeat, Humans, Signal Transduction, HIV-1 physiology, Intercellular Adhesion Molecule-1 physiology
- Abstract
Human immunodeficiency virus type 1 (HIV-1) acquires several host cell membrane proteins when it buds from infected cells. To study the effect of virally incorporated host-derived ICAM-1 glycoproteins on the biology of HIV-1, we have developed a transient expression system that has enabled us to produce virus particles differing only in the absence or the presence of virion-bound ICAM-1. By using a single-round infection assay based on an ICAM-1-negative target T-cell line stably transfected with an HIV-1 long terminal repeat driven luciferase gene construct, we have been able to demonstrate that the acquisition of host-derived ICAM-1 by HIV-1 has functional significance, since it leads to a pronounced increase in viral infectivity (4.6- to 9.8-fold) in an ICAM-1/LFA-1-dependent fashion, as shown by blocking with anti-ICAM-1 and -LFA-1 antibodies. The same potentiating effect on viral infectivity was also observed with monocytoid cells. Studies of the kinetics of infection revealed that the positive effect mediated by virally embedded host cell membrane ICAM-1 is due to an increase in the efficiency of early steps in the viral life cycle. These results provide new insights into how incorporation of host proteins can modulate the biological properties of HIV-1. Our findings have direct clinical relevance, considering that ICAM-1 is expressed on the surface of virus-infected cells and, more importantly, that host-derived ICAM-1 has been shown to be acquired by clinical HIV-1 isolates grown on primary mononuclear cells. These data justify a more complete analysis of the other putative role(s) that virally incorporated ICAM-1 may play in the life cycle of HIV-1, for example, at the level of neutralization sensitivity.
- Published
- 1997
- Full Text
- View/download PDF
25. CD4 deletion mutants evaluated for human immunodeficiency virus type 1 infectivity in a highly efficient system of expression and detection based on LTR-dependent reporter gene activation.
- Author
-
Moir S, Boissinot M, Tremblay M, and Poulin L
- Subjects
- Animals, CHO Cells, Cell Line, Cricetinae, Flow Cytometry, HIV Envelope Protein gp120 analysis, HIV-1 genetics, HIV-1 pathogenicity, Humans, Molecular Sequence Data, Mutagenesis, Site-Directed, Polymerase Chain Reaction, Protein Binding, Protein Structure, Tertiary, Transcriptional Activation, CD4 Antigens genetics, CD4 Antigens metabolism, Gene Expression Regulation, Viral, Genes, Reporter, HIV Long Terminal Repeat, HIV-1 metabolism, Sequence Deletion
- Abstract
The human CD4 glycoprotein is thought to be involved at several stages of the infection process with the human immunodeficiency virus type 1. To pursue this line of investigation with CD4 deletion mutants, we combined a system of high transient cell-surface expression of the target molecule with an assay of HIV-1 infectivity based on induction of LTR-linked luciferase activity. The approach was also designed to distinguish between defects in gp120 binding and postbinding events. Optimal assay conditions were established with wild-type CD4 and the previously characterized CD4 mutant, d367-371. New deletions of CD4 domains D3 and D4 were then designed from a rat model of the D3D4 atomic coordinates with the concern of maintaining overall structural integrity. While all CD4 mutants were found to be defective towards HIV, it was demonstrated that the mutations affected different stages of the entry process. These data indicate that the system is well suited for studying the intricacy of molecular interactions involving HIV envelope glycoproteins and its receptors.
- Published
- 1997
- Full Text
- View/download PDF
26. Enhancement of HIV-1-induced syncytium formation in T cells by the tyrosyl kinase p56lck.
- Author
-
Briand G, Barbeau B, Corbeil J, and Tremblay M
- Subjects
- Cell Line, Cell Line, Transformed, Giant Cells virology, Humans, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), T-Lymphocytes cytology, T-Lymphocytes metabolism, Virus Replication, src-Family Kinases genetics, HIV-1 pathogenicity, T-Lymphocytes virology, src-Family Kinases metabolism
- Abstract
The CD4 glycoprotein is the primary cellular receptor for human immunodeficiency virus type 1 (HIV-1) and has also been reported to be physically associated with p56lck, a tyrosyl protein kinase p56lck is a member of the src family of nonreceptor protein-tyrosine kinases and is expressed predominantly in T lymphocytes. Our objective was to study the effect of p56lck on the biology of HIV-1. For this purpose, we have stably transfected two human p56lck negative T cell lines (C8166-45 and MT-2) with plasmids encoding for this cellular protein. Following coculture with HIV-1-infected cells or infection with cell-free virus, p56lck-expressing cell lines showed a greater propensity for virus-mediated syncytium formation than parental p56lck-negative cells. The enhancement of HIV-1-induced syncytium formation was not associated with the kinase activity of p56lck, as demonstrated by experiments using a kinase-deficient mutant. However, the physical interaction between CD4 and p56lck was shown to be necessary to obtain the enhancement of syncytium formation since a mutated version of p56lck, which is deficient in its capacity to associate with CD4, did not lead to an increase in virus-mediated cell-to-cell fusion events. Finally, we determined that cells transfected with wild-type and kinase-negative mutant p56lck showed a reduced rate of CD4 endocytosis compared to parental p56lck-negative cells. Together, these results suggest that p56lck can be seen as an accessory molecule facilitating HIV-1-mediated syncytium formation in T cells by a mechanism involving the stabilization of the CD4 molecule at the cell surface.
- Published
- 1997
- Full Text
- View/download PDF
27. The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.
- Author
-
Cantin R, Fortin JF, Lamontagne G, and Tremblay M
- Subjects
- Cell Line, Cell Line, Transformed, Cells, Cultured, HIV Core Protein p24 analysis, HIV-1 genetics, HIV-1 metabolism, HLA-DR1 Antigen genetics, Humans, Jurkat Cells, Kinetics, Leukocytes, Mononuclear cytology, Leukocytes, Mononuclear virology, Luciferases genetics, Luciferases metabolism, Tumor Cells, Cultured, Virion, HIV-1 pathogenicity, HLA-DR1 Antigen metabolism
- Abstract
Human immunodeficiency virus type 1 (HIV-1) incorporates several host cell components when budding out of the infected cell. One of the most abundant host-derived molecules acquired by HIV-1 is the HLA-DR determinant of the major histocompatibility complex class II (MHC-II) molecules. The fact that CD4 is the natural ligand of MHC-II prompted us to determine if such virally embedded cellular components can affect the biology of the virus. Herein, we report for the first time that the incorporation of cellular HLA-DR1 within HIV-1 enhances its infectivity. This observation was made possible with virions bearing or not bearing on their surfaces host-derived HLA-DR1 glycoproteins. Such virus stocks were prepared by a transient-expression system based on transfection of 293T cells with a recombinant luciferase-encoding HIV-1 molecular clone along with plasmids encoding the alpha and beta chains of HLA-DR1. Cell-free virions recovered from transfected cells were shown to have efficiently incorporated host-derived HLA-DR1 glycoproteins. Infectivity was increased by a factor of 1.6 to 2.3 for virions bearing on their surfaces host-derived HLA-DR1. The observed enhancement of HIV-1 infectivity was independent of the virus stocks used and was seen in several T-lymphoid cell lines, in a premonocytoid cell line, and in primary peripheral blood mononuclear cells. Finally, we determined that the presence of virion-bound cellular HLA-DR1 is associated with faster kinetics of virus infection. Taken together, these results suggest that HLA-DR-1-bearing HIV-1 particles had a greater infectivity per picogram of viral p24 protein than HLA-DR1-free virions.
- Published
- 1997
- Full Text
- View/download PDF
28. Binding of HIV-1 to its receptor induces tyrosine phosphorylation of several CD4-associated proteins, including the phosphatidylinositol 3-kinase.
- Author
-
Briand G, Barbeau B, and Tremblay M
- Subjects
- Animals, CD4 Antigens metabolism, CD4-Positive T-Lymphocytes cytology, Humans, Jurkat Cells, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), Mice, Phosphatidylinositol 3-Kinases, Phosphorylation, Tumor Cells, Cultured, HIV-1 metabolism, Phosphotransferases (Alcohol Group Acceptor) metabolism, Receptors, HIV metabolism, Tyrosine metabolism, src-Family Kinases metabolism
- Abstract
Cell surface CD4 molecules are known to be important in several physiological responses of T lymphocytes. The use of human immunodeficiency virus (HIV) particles or purified gp120 molecules as CD4 cross-linking agents has been shown to result in a cascade of intracellular biochemical events. In addition, we and other have provided evidence suggesting that virus-mediated CD4 multimerization can lead to modulation of HIV-1 long terminal repeat-dependent activity and virus production. We were thus interested in measuring the effect of HIV-1 particles on intracellular tyrosine-phosphorylation levels, mostly of CD4-associated proteins. Using the T cell line CEM-T4, we observed that HIV-1 induces an increase in tyrosine phosphorylation of four major proteins physically complexed to the CD4 molecule. Immunoblot analysis permitted the identification of two of these proteins, p56lck and phosphatidylinositol 3-kinase (PI 3-kinase) p85 alpha. No concomitant variation in the level of these two CD4-associated proteins was observed after HIV-1-induced CD4 cross-linking. To our knowledge, this is the first report linking HIV-1-mediated CD4 multimerization to an increase in tyrosine phosphorylation of the PI 3-kinase complex. The four CD4-associated molecules described in this report are most likely implicated in virus-induced CD4-linked signaling events.
- Published
- 1997
- Full Text
- View/download PDF
29. Drug sensitivity of human immunodeficiency virus type 1 isolates after ribavirin therapy.
- Author
-
Bernier R, Tremblay M, Tsoukas C, and Bergeron MG
- Subjects
- Adult, Anti-HIV Agents therapeutic use, Double-Blind Method, Drug Resistance, Microbial, HIV Infections virology, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Ribavirin therapeutic use, Anti-HIV Agents pharmacology, HIV Infections drug therapy, HIV-1 drug effects, Ribavirin pharmacology
- Abstract
The antiviral agent ribavirin is effective against several virally induced diseases, and there is evidence that it might prove useful against human immunodeficiency virus type 1 (HIV-1) infection. Thus, there is interest in studying the resistance level of HIV-1 isolates to ribavirin following drug therapy. Low-passage clinical strains of HIV-1 were isolated from 3 patients undergoing treatment with ribavirin for 5-9 months. No significant changes in drug sensitivity were seen for sequential virus samples obtained before, during, and after antiviral therapy. These observations suggest that the appearance of a resistant phenotype is not induced by treatment with ribavirin in HIV-1-infected persons.
- Published
- 1997
- Full Text
- View/download PDF
30. Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.
- Author
-
Bérubé P, Barbeau B, Cantin R, Sékaly RP, and Tremblay M
- Subjects
- Cell Line, Gene Products, tat physiology, HIV Envelope Protein gp120 physiology, HIV-1 physiology, Humans, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), NF-kappa B metabolism, Tetradecanoylphorbol Acetate pharmacology, src-Family Kinases physiology, tat Gene Products, Human Immunodeficiency Virus, CD4 Antigens physiology, Gene Expression Regulation, Viral, HIV Long Terminal Repeat, HIV-1 genetics
- Abstract
We have previously postulated that the binding of the human immunodeficiency virus type 1 (HIV-1) to cell surface CD4 induces signal transduction pathways that down-modulate production of progeny virions in acutely infected T cells (M. Tremblay, S. Meloche, S. Gratton, M. A. Wainberg, and R.-P. Sékaly, EMBO J. 13:774-783, 1994). To evaluate the possibility that CD4 cross-linking might indeed affect viral gene expression, we have introduced a molecular construct made of the luciferase reporter gene placed under the control of the regulatory elements of HIV-1 in several CD4-positive T-cell lines. We found that cross-linking of CD4 with defective HIV-1 particles and heat-inactivated viruses inhibits long terminal repeat-dependent luciferase expression. Experiments revealed that the gp120-CD4 interaction was necessary to repress HIV-1 long terminal repeat-dependent luciferase activity. The cytoplasmic domain of CD4 was also found to be required for this effect to occur. The virus-mediated signal transduction was shown to be mediated via p56lck-dependent and -independent pathways. These results indicate that the earliest event in the HIV-1 replicative cycle, namely, the binding of the virus to its cellular receptor, can lead to signal transduction culminating in down-modulation of viral gene expression. Thus we propose that defective viruses could regulate the pathogenesis of HIV disease as they constitute the vast majority of circulating HIV-1 particles.
- Published
- 1996
- Full Text
- View/download PDF
31. The amount of host HLA-DR proteins acquired by HIV-1 is virus strain- and cell type-specific.
- Author
-
Cantin R, Fortin JF, and Tremblay M
- Subjects
- Antibodies, Monoclonal, CD4 Antigens analysis, Cell Line, Cells, Cultured, HIV Core Protein p24 analysis, HLA-DP Antigens analysis, HLA-DQ Antigens analysis, Histocompatibility Antigens Class I analysis, Humans, Immunomagnetic Separation, Intercellular Adhesion Molecule-1 analysis, Leukocytes, Mononuclear virology, Species Specificity, Virus Assembly, CD4-Positive T-Lymphocytes virology, HIV-1 physiology, HLA-DR Antigens analysis, Virion chemistry
- Abstract
We semiquantitatively monitored the incorporation of host membrane proteins on different strains of human immunodeficiency virus type 1 (HIV-1) grown in several human CD4+ lymphoid cell lines and in primary mitogen-stimulated peripheral blood mononuclear cells. The relative amounts of virally acquired cell proteins were estimated by the ability of HIV-1 to be captured by magnetic beads coated with monoclonal antibodies. Here we report that, among host surface proteins studied, HLA-DR molecules were the most abundant virion-bound host molecules. We have also found that, in contrast to previous studies, HLA-DP and -DQ isotypes were also present on virus progeny. More importantly, we determined that the relative levels of virally acquired host HLA-DR proteins, as estimated by capture with immunomagnetic beads, greatly differed depending on the virus strain and the producer cell. These observations extend beyond already published results and suggest that the process of incorporation of cellular molecules on newly released virus particles is a phenomenon that relies on both the virus strain and producer cell line. These in vitro observations are of prime importance considering that virus-acquired host molecules have been recently shown to affect the biology of HIV.
- Published
- 1996
- Full Text
- View/download PDF
32. HIV-induced apoptosis requires the CD4 receptor cytoplasmic tail and is accelerated by interaction of CD4 with p56lck.
- Author
-
Corbeil J, Tremblay M, and Richman DD
- Subjects
- Base Sequence, CD4 Antigens genetics, CD4-Positive T-Lymphocytes virology, Cell Fusion, Cell Transformation, Viral, Cytopathogenic Effect, Viral, Flow Cytometry, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), Molecular Sequence Data, Peptide Fragments metabolism, Precipitin Tests, Protein Binding, Apoptosis, CD4 Antigens metabolism, CD4-Positive T-Lymphocytes pathology, HIV-1 growth & development, Signal Transduction, src-Family Kinases metabolism
- Abstract
The roles of the CD4 receptor and the src kinase p56lck were examined in the process of HIV-induced apoptosis of CD4+ T lymphocytes. The presence of the CD4 cytoplasmic tail was found to be essential in delivering an apoptotic signal, and interaction of CD4 with p56lck potentiated HIV-induced apoptosis. Apoptosis, but not HIV replication, was abrogated by deleting the NH2-terminal intracytoplasmic tail of CD4, or by mutating the two critical cysteines in this tail that are responsible for CD4-p56lck interaction. Introduction of p56lck in C8166-45 or MT-2 cells, CD4+ T cell lines deficient for this protein, greatly increased HIV-induced apoptosis and syncytium formation. The ability of p56lck to deliver an apoptotic signal did not depend on its kinase function, since a kinase-deficient mutant was as effective as its normal counterpart in inducing apoptosis, suggesting that p56lck may act as an adapter to anchor other proteins to transduce the death signal.
- Published
- 1996
- Full Text
- View/download PDF
33. Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani.
- Author
-
Bernier R, Turco SJ, Olivier M, and Tremblay M
- Subjects
- Acquired Immunodeficiency Syndrome physiopathology, Animals, Antibodies pharmacology, Cell Differentiation, Cell Line, HIV-1 drug effects, HIV-1 growth & development, Humans, Monocytes, Tetradecanoylphorbol Acetate pharmacology, Tumor Necrosis Factor-alpha immunology, Virus Latency, Glycosphingolipids pharmacology, HIV-1 physiology, Leishmania donovani physiology, Tumor Necrosis Factor-alpha biosynthesis, Virus Activation drug effects
- Abstract
In this study, we demonstrated that the protozoan parasite Leishmania donovani and one of its major surface molecules, the lipophosphoglycan (LPG), can induce human immunodeficiency virus type 1 (HIV-1) expression in U1 and OM-10.1, two cell lines of monocytoid origin latently infected with HIV-1. Treatment of U1 cells with various concentrations of LPG (1, 5, and 10 microM) resulted in a dose-dependent secretion of tumor necrosis factor alpha (TNF-alpha). Suppression of LPG-induced HIV-1 expression by polyclonal anti-TNF-alpha antibodies further confirmed the involvement of this cytokine. Results from these studies indicate that the protozoan parasite L. donovani can induce the secretion of TNF-alpha that will function in an autocrine or paracrine manner to upregulate HIV-1 expression. Our data suggest for the first time that this protozoan parasite can be viewed as a potential cofactor in the pathogenesis of AIDS.
- Published
- 1995
- Full Text
- View/download PDF
34. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics.
- Author
-
Dusserre N, Lessard C, Paquette N, Perron S, Poulin L, Tremblay M, Beauchamp D, Désormeaux A, and Bergeron MG
- Subjects
- Animals, Antiviral Agents pharmacology, Base Sequence, Cell Line, DNA Primers genetics, DNA, Viral genetics, Female, Foscarnet pharmacology, HIV-1 genetics, Humans, Injections, Intravenous, Liposomes, Macrophages metabolism, Molecular Sequence Data, Polymerase Chain Reaction, Rats, Rats, Sprague-Dawley, Tissue Distribution, Antiviral Agents administration & dosage, Antiviral Agents pharmacokinetics, Foscarnet administration & dosage, Foscarnet pharmacokinetics, HIV-1 drug effects
- Abstract
Objective: To improve the in vitro anti-HIV-1 activity, intracellular accumulation in macrophages and in vivo pharmacokinetics and tissue distribution of foscarnet (trisodium phosphonoformate; PFA) by encapsulation in liposomes., Methods: The accumulation of free and liposome-encapsulated PFA was determined in monocyte-macrophage RAW 264.7 cells and human premonocytoid U937 cells. The antiviral activity was evaluated in U937 cells infected with HIV-1IIIB. Tissue distribution and pharmacokinetics of free and liposomal PFA were determined in female Sprague-Dawley rats following the administration of an intravenous bolus dose (10 mg PFA/kg)., Results: The entrapment of PFA in liposomes resulted in a higher drug accumulation in both U937 and RAW 264.7 cells. A slightly greater efficacy against HIV-1IIIB replication into U937 cells was observed upon encapsulation of PFA into liposomes. Improved pharmacokinetics was observed upon entrapment of PFA in liposomes. Much higher drug levels were found in plasma for the liposomal formulation. The systemic clearance of the liposomal drug was 77 times lower than that of free drug. The encapsulation of PFA in liposomes greatly enhanced the drug accumulation in organs of the reticuloendothelial system., Conclusion: The encapsulation of PFA in liposomes modified the tissue distribution and plasma pharmacokinetics of the antiviral agent, resulting in a marked improvement of drug accumulation in organs involved in HIV immunopathogenesis and in a greater PFA bioavailability. The antiviral activity of liposomal PFA was slightly greater than that of free drug in HIV-1IIIB-infected U937 cells.
- Published
- 1995
- Full Text
- View/download PDF
35. Homologous interference resulting from the presence of defective particles of human immunodeficiency virus type 1.
- Author
-
Bernier R and Tremblay M
- Subjects
- CD4 Antigens metabolism, Cell Division, Cell Line, Defective Viruses physiology, HIV-1 physiology, Humans, Virion genetics, Virus Replication genetics, Defective Viruses genetics, HIV-1 genetics, Viral Interference
- Abstract
Defective particles are naturally occurring virus mutants that lack one or more genes required for viral replication. Such viruses may affect positively or negatively the symptoms of the disease. Thus, it is of great interest to measure the role played by defective particles in the process of human immunodeficiency virus (HIV) infection since accumulating evidence indicates that a great proportion of HIV genomes are defective. We used defective particles produced by two stable cellular clones (UHC-8 and UHC-18) to investigate whether they can affect replication of infectious viral particles generated by a human T-cell line transfected with a molecular HIV-1 clone. Progeny virus harvested from UHC-8 cells has no reverse transcriptase and integrase proteins, while UHC-18 has no reverse transcriptase protein. We demonstrate here that coinoculation of a T-lymphoid cell line and of peripheral blood mononuclear cells with defective and infectious particles leads to a dramatic inhibition of virus replication. Defective particles do not interfere with virus production from proviral DNA. Rather, the inhibition of reinfection events seems to be their mechanism of action. This model closely parallels the in vivo conditions and demonstrates that defective particles may limit the spread of infection and progression of the disease by reducing the yield of infectious virus.
- Published
- 1995
- Full Text
- View/download PDF
36. Association of p56lck with the cytoplasmic domain of CD4 modulates HIV-1 expression.
- Author
-
Tremblay M, Meloche S, Gratton S, Wainberg MA, and Sékaly RP
- Subjects
- Base Sequence, CD4 Antigens genetics, CD4 Antigens immunology, Cytoplasm metabolism, Humans, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), Molecular Sequence Data, RNA, Viral metabolism, Signal Transduction, T-Lymphocytes immunology, T-Lymphocytes microbiology, Tumor Cells, Cultured, Viral Proteins metabolism, Virus Integration, Virus Replication, CD4 Antigens metabolism, HIV-1 physiology, Protein-Tyrosine Kinases metabolism
- Abstract
To investigate the role played by the cytoplasmic domain of the CD4 glycoprotein in the process of HIV infection, we have transfected two CD4-negative human T cell lines with cDNAs encoding the full-length CD4 and a truncated form of the molecule, lacking most of the cytoplasmic domain. Levels of viral replication were significantly higher in cells carrying the truncated version of CD4, in comparison with cells expressing the full-length CD4, as measured by the percentage of cells expressing viral p24 protein and the number of infectious particles released into culture supernatants. The extent of viral entry and reverse transcription was similar in each case, as monitored by an enzymatic test and quantitative PCR. Quantitative differences at RNA and protein levels were responsible for changes in viral production. To further characterize the mechanisms responsible for decreased rates of HIV replication in CD4-expressing cells we have treated the different cell lines, very early after HIV infection, with azidothymidine and soluble CD4, two antiviral agents that inhibit replication of HIV at different stages in the virus replicative cycle. Results from these experiments indicate that a cellular signal is mediated by the CD4 molecule, which negatively regulates the expression of viral DNA already present in such cells. This signal would be initiated following oligomerization of the CD4 molecule by the virus itself. Results from experiments with a CD4 construct containing mutations of the cysteine residues which are responsible for association of CD4 with p56lck demonstrate that p56lck is implicated in the transduction of the signal negatively regulating HIV replication.
- Published
- 1994
- Full Text
- View/download PDF
37. Zidovudine-resistant and -sensitive HIV-1 isolates from patients on drug therapy: in vitro studies evaluating level of replication-competent viruses and cytopathogenicity.
- Author
-
Tremblay M, Rooke R, and Wainberg MA
- Subjects
- Acquired Immunodeficiency Syndrome drug therapy, Acquired Immunodeficiency Syndrome physiopathology, Cell Survival, Cytopathogenic Effect, Viral, Drug Resistance, Microbial, Genetic Variation, HIV Core Protein p24 analysis, HIV-1 drug effects, Humans, Phenotype, Selection, Genetic, Acquired Immunodeficiency Syndrome microbiology, HIV-1 growth & development, Zidovudine pharmacology
- Abstract
Objective: To compare biological properties of zidovudine-resistant variants of HIV-1 isolated from subjects on long-term drug therapy with drug-sensitive parental isolates obtained from the same patients before initiation of treatment., Methods: Clinical HIV-1 strains were isolated following co-incubation of patient peripheral blood mononuclear cells with mitogen-stimulated umbilical cord blood lymphocytes. Drug resistance was evaluated by infecting MT-4 cells pretreated with zidovudine and maintained under drug pressure., Results: The drug-resistant phenotype remained stable, following many viral replication cycles in the absence of zidovudine. Drug-resistant variants contained fewer replication-competent viruses but were more cytopathogenic than their corresponding zidovudine-sensitive parental strains., Conclusions: These results suggest that drug-resistant strains possess biological properties that may differ from those of drug-sensitive variants of HIV-1.
- Published
- 1992
- Full Text
- View/download PDF
38. Characterization of zidovudine resistant variants of HIV-1 isolated from patients on prolonged therapy.
- Author
-
Wainberg MA, Tremblay M, Rooke R, Fanning M, Tsoukas C, Montaner JS, O'Shaughnessy M, and Ruedy J
- Subjects
- Blotting, Southern, Drug Resistance, Microbial, HIV Infections drug therapy, HIV-1 pathogenicity, Humans, Time Factors, HIV Infections microbiology, HIV-1 drug effects, Zidovudine pharmacology
- Abstract
As part of a clinical trial to assess zidovudine related toxic effects, the authors followed 48 initially asymptomatic individuals who received prolonged therapy with this drug at several tertiary care institutions. Blood samples had been obtained for viral isolation every three months and had yielded infectious HIV-1 progeny in over 94 percent of cases. After one year of therapy, over 30 percent of individuals had developed variants of HIV-1 that displayed in vitro resistance to zidovudine. Six of these zidovudine resistant variants of HIV-1 were compared with drug sensitive isolates obtained from the same subjects prior to initiation of treatment. The drug resistant variants were generally as infectious per mg viral protein for both susceptible T cell lines and peripheral blood mononuclear cells as the corresponding parental isolates from which they were derived. The drug resistance phenotype remained stable, in that zidovudine-insensitive species could still be identified, following many replication cycles in the absence of drug pressure. However, the percentage of zidovudine resistant viruses appeared to diminish in culture over time under such conditions. This was demonstrated by the fact that lower percentages of cells became infected in the presence of the drug, if the viruses used for infection had been propagated in the absence of the drug. In addition, higher concentrations of such viruses were required to initiate infection in the presence of the drug, and these viruses possessed lower IC50's for zidovudine. This suggests that zidovudine resistant variants of HIV-1 may be unlikely to possess any growth advantage in the absence of the drug.
- Published
- 1992
39. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs.
- Author
-
Rooke R, Parniak MA, Tremblay M, Soudeyns H, Li XG, Gao Q, Yao XJ, and Wainberg MA
- Subjects
- Acquired Immunodeficiency Syndrome blood, Acquired Immunodeficiency Syndrome microbiology, Antiviral Agents pharmacology, Cytosine analogs & derivatives, Cytosine pharmacology, Drug Resistance, Microbial, Humans, Lamivudine, Nucleosides pharmacology, Viral Plaque Assay, Virus Replication drug effects, Zalcitabine pharmacology, HIV-1 drug effects, Zidovudine pharmacology
- Abstract
We used a viral endpoint dilution assay to show changes in the proportion of zidovudine (azidothymidine; AZT)-resistant viruses within a heterogeneous mixture of human immunodeficiency virus type 1 (HIV-1) quasispecies isolated from patients on long-term AZT therapy. Several HIV-1 isolates, which could replicate in 10 microM AZT, were susceptible to both 2',3'-dideoxycytidine and a novel cytosine analog BCH-189, in which a sulfur atom replaces the 3' carbon of the pentose ring. In certain instances, cross-resistance was seen with 3'-didehydro-2',3'-dideoxythymidine. Although most strains of AZT-resistant HIV-1 displayed reduced susceptibility to 3'-azido-2',3'-dideoxyuridine, two strains were identified for which this was not the case.
- Published
- 1991
- Full Text
- View/download PDF
40. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
- Author
-
Tremblay M, Numazaki K, Li XG, Gornitsky M, Hiscott J, and Wainberg MA
- Subjects
- Adult, B-Lymphocytes immunology, Blotting, Western, HIV Antigens immunology, HIV Infections immunology, HIV Seropositivity immunology, HIV-1 immunology, Humans, In Vitro Techniques, Middle Aged, Neutralization Tests, RNA-Directed DNA Polymerase metabolism, HIV Antibodies immunology, HIV Infections microbiology, HIV-1 growth & development, Leukocytes, Mononuclear microbiology
- Abstract
We have investigated whether PBMC of HIV-1-seropositive subjects are as susceptible to in vitro infection by HIV-1 as are PBMC from seronegative controls. Accordingly, stimulated PBMC from 19 HIV-1-infected subjects were inoculated with four different variants of HIV-1. None of these cultures produced either detectable quantities of viral reverse transcriptase activity or p24 Ag following inoculation with HIV-1. In contrast, in five of six cases in which these PBMC were depleted of B cells by antibody plus complement prior to viral inoculation, the presence of viral reverse transcriptase and p24 Ag was detected. The presence of normal levels of CD4-Ag at the surface of the CD4+ cells in these populations was established by flow cytometry. Analysis by an immunoblot assay revealed that anti-HIV antibodies were present in the sera obtained from these infected donors; in addition, 7 of 10 culture fluids derived from the nondepleted PBMC were shown to contain virus-neutralizing antibodies. Cultures which were depleted of B cells did not contain detectable levels of antiviral antibodies. Confirmation that the virus produced by the PBMC which had been depleted of B cells was of the strain used to infect the cultures, rather than that which initially caused patient infection, was provided on the basis of differential susceptibility to antibody neutralization. These results suggest that antibodies produced by B cells in cultures of PBMC from seropositive donors may restrict infection by HIV-1 of such cultures under laboratory conditions.
- Published
- 1990
41. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.
- Author
-
Tremblay M and Wainberg MA
- Subjects
- Adult, Cell Line, HIV Infections immunology, Humans, Neutralization Tests, HIV Antibodies immunology, HIV Infections microbiology, HIV-1 immunology
- Abstract
Titers of neutralizing antibodies to different strains of human immunodeficiency virus type 1 (HIV-1), including five isolates sequentially obtained from one infected subject, were determined using sequential serum samples obtained from that individual. Neutralizing antibodies were detected against the HIV-IIIB laboratory strain of HIV-1 and against a clinical isolate from another HIV-1-infected individual. Sera from the subject under investigation possessed differential ability to enact viral neutralization, depending on which homotypic clinical isolate was used. In general, it appeared that effective neutralization capacity was present in serum against homotypic viral isolates of HIV-1 only if these isolates were obtained at or before serum collection. These data suggest that variants of HIV-1 in infected individuals may not be effectively neutralized by antibodies that have been generated in these same people against previously dominant viral strains.
- Published
- 1990
- Full Text
- View/download PDF
42. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells.
- Author
-
Rooke R, Tremblay M, and Wainberg MA
- Subjects
- Cell Survival, Cells, Cultured, Gene Products, gag immunology, HIV Antigens analysis, HIV Core Protein p24, HIV-1 growth & development, HIV-1 immunology, HIV-1 ultrastructure, Humans, Neutrophils microbiology, RNA-Directed DNA Polymerase metabolism, Viral Core Proteins immunology, Virus Replication, Acquired Immunodeficiency Syndrome drug therapy, HIV-1 drug effects, Zidovudine pharmacology
- Abstract
The reverse transcriptase enzyme of HIV-1 is known to be error-prone. We were interested in the possibility of isolating a variant HIV-1 strain that might be capable of replication in the presence of AZT, thought to act by antagonizing reverse transcriptase activity. Toward this end, chronically infected H-9 cells were exposed to various concentrations of AZT for at least 500 days. No mutant has yet arisen from such cultures, which continued to produce high levels of each of the viral proteins p24, p17, gp41, and gp51/66 in the presence of the drug. Notwithstanding such expression of viral antigens, culture fluids from these various AZT-treated cultures were not capable of infecting otherwise susceptible target cells. Electron microscopic observations of AZT-treated chronically infected H-9 cells indicated a lower production of viral structures, in comparison with control cultures. Furthermore, those particles seen at the plasma membrane of AZT-treated cells often appeared to be envelope-deficient. These data suggest that AZT may be able to interfere in some way with proper assembly and/or packaging of infectious progeny HIV-1 at the cell membrane, although other modes of action for a postintegrational effect of AZT cannot be excluded.
- Published
- 1990
- Full Text
- View/download PDF
43. Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells.
- Author
-
Tremblay M, Meloche S, Sekaly RP, and Wainberg MA
- Subjects
- Antibodies, Monoclonal, Antigens, CD analysis, CD4 Antigens analysis, Cell Line, Cell Transformation, Viral, Flow Cytometry, HIV-1 physiology, Humans, Macrophage-1 Antigen, Virus Replication, B-Lymphocytes immunology, HIV-1 genetics, Herpesvirus 4, Human genetics, Receptors, Complement physiology
- Abstract
Although the CD4 glycoprotein is the primary receptor for HIV-1, recent reports have suggested that other molecules might be involved in the enhancement of HIV-1 infection. We investigated the possible role of the complement receptor 2 in enhancement of HIV-1 infection in CD4+ EBV-containing B cells by infecting such cells in the presence of sera from HIV sero-positive donors, with or without added human complement. A marked increase in production of viral p24 and infectious progeny virus was observed only when infection had been carried out in the presence of human complement. The addition of mAb to the human complement receptor 2 completely inhibited this enhancement. This mechanism was CD4 dependent, suggesting a cooperative effect between these two ligands in the potentiation of viral entry.
- Published
- 1990
- Full Text
- View/download PDF
44. Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study.
- Author
-
Wainberg MA, Tremblay M, Rooke R, Blain N, Soudeyns H, Parniak MA, Yao XJ, Li XG, Fanning M, and Montaner JS
- Subjects
- Acquired Immunodeficiency Syndrome epidemiology, Canada epidemiology, Cells, Cultured, Drug Resistance, Microbial genetics, Genetic Variation, HIV-1 enzymology, HIV-1 genetics, HIV-1 isolation & purification, Humans, Kinetics, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear microbiology, Membrane Glycoproteins metabolism, Nucleosides therapeutic use, Sensitivity and Specificity, Viral Envelope Proteins metabolism, Zidovudine therapeutic use, Acquired Immunodeficiency Syndrome drug therapy, HIV-1 drug effects, Nucleosides pharmacology, RNA-Directed DNA Polymerase metabolism, Zidovudine pharmacology
- Published
- 1990
- Full Text
- View/download PDF
45. Infection of human thymic lymphocytes by HIV-1.
- Author
-
Tremblay M, Numazaki K, Goldman H, and Wainberg MA
- Subjects
- Cells, Cultured, Child, Preschool, Fetal Blood cytology, Gene Products, gag analysis, HIV Antigens analysis, HIV Core Protein p24, Humans, Infant, RNA-Directed DNA Polymerase metabolism, T-Lymphocytes immunology, Viral Core Proteins analysis, HIV-1 enzymology, T-Lymphocytes microbiology
- Abstract
We have succeeded in infecting human thymic lymphocytes with both the HIV-IIIB laboratory strain of HIV-1 as well as with a clinical isolate of this virus. Thymic lymphocytes were at least as susceptible to infection by HIV-1 as were cord blood lymphocytes, but appeared to display somewhat greater resistance to the cytopathic effects of the virus. As measured variously by each of indirect immunofluorescence for detection of viral p17, antigen capture assay for the presence of viral p24 in culture fluids, and levels of viral reverse transcriptase activity in culture fluids, infection of thymic lymphocytes could be detected as early as 2 days after infection by HIV-1, and persisted through at least 14 days of tissue culture maintenance. These findings suggest that thymic lymphocytes may be susceptible to infection by HIV-1 in vivo, and may also be relevant to our understanding of HIV-1-induced pathogenesis, particularly in pediatric populations.
- Published
- 1990
46. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1.
- Author
-
Wainberg MA, Dascal A, Blain N, Fitz-Gibbon L, Boulerice F, Numazaki K, and Tremblay M
- Subjects
- Cell Line, HIV-1 physiology, Humans, Tumor Cells, Cultured drug effects, CD4-Positive T-Lymphocytes drug effects, Cyclosporins pharmacology, HIV-1 drug effects, Leukocytes, Mononuclear drug effects, Macrophages drug effects, Monocytes drug effects, Virus Replication drug effects
- Abstract
The effect of cyclosporine A (CyA) on the ability of the human immunodeficiency virus type 1 (HIV-1) to infect the H-9 T-cell leukemic line, as well as interleukin-2 (IL-2)-grown human peripheral blood-derived lymphocytes, has been studied. Pretreatment of H-9 cells and human lymphocytes with CyA over 24 hours completely prevented viral infection over a 21-day period, whereas the addition of drug at two hours postinfection with HIV-1 had a significant inhibitory effect on viral replication and expression of the virus-specific antigens p17 and p24. However, if CyA was added at later times to these lymphocytic cells, this inhibitory effect was lost. Indeed, the removal of CyA from cultures that had been treated from two hours after infection led to the rapid production of progeny virus. HIV-1 was able to infect peripheral blood lymphocytes obtained from each of four kidney allograft recipients on long-term CyA antirejection therapy, as long as drug was not included in the culture medium. In addition, we asked what effect pretreatment with CyA of cells of the U-937 monocytic line and primary cultures of human monocytes/macrophages might have on infection by HIV-1. CyA had no demonstrable effect on the ability of HIV-1 to infect cells of either type.
- Published
- 1988
47. Active replication of human immunodeficiency virus type 1 by peripheral blood mononuclear cells following coincubation with herpes viruses.
- Author
-
Tremblay M, Gornitsky M, and Wainberg MA
- Subjects
- Adult, Antibodies, Monoclonal immunology, Child, Preschool, Cytomegalovirus physiology, HIV Seropositivity, Humans, Virus Replication, HIV-1 growth & development, Neutrophils microbiology, Simplexvirus growth & development
- Abstract
Patients with acquired immunodeficiency syndrome (AIDS) commonly suffer from opportunistic infections associated with members of the herpes virus family. To investigate whether certain of these other viruses might have an effect on the ability of the human immunodeficiency virus type 1 (HIV-1) to replicate, we coincubated peripheral blood mononuclear cells (PBMC) from nine HIV-1-seropositive donors with live preparations of various herpes viruses. In seven of nine cases, exposure of PBMC to preparations of either HSV-1, HSV-2, or CMV stimulated the cells to become active producers of HIV-1, as determined by reverse transcriptase activity and by the presence of infectious progeny virus. This increased production of HIV-1 particles appeared to be a consequence of mitogenic proliferation and of herpes virus-encoded transacting factors. These results supplement earlier findings on the molecular activation of the HIV-1 genome by both HSV and CMV genetic elements and point to a possible role for these viruses in the pathogenesis and ultimate clinical outcome of HIV-1 infections.
- Published
- 1989
- Full Text
- View/download PDF
48. Susceptibility to AZT of HIV-1 variants grown in Epstein-Barr virus-transformed B cell lines.
- Author
-
Tremblay M and Wainberg MA
- Subjects
- B-Lymphocytes drug effects, Cell Line, Transformed, Cell Survival drug effects, Enzyme-Linked Immunosorbent Assay, Fluorescent Antibody Technique, HIV Antigens analysis, HIV Core Protein p24, HIV-1 physiology, Humans, Retroviridae Proteins analysis, Virus Replication drug effects, B-Lymphocytes microbiology, HIV-1 drug effects, Herpesvirus 4, Human physiology, Zidovudine pharmacology
- Abstract
How 3'-azido-3'-deoxythymidine (AZT) affects the ability of three different variants of HIV-1 to infect a line of EBV-transformed B cells was studied. Susceptible cells were pretreated with three different concentrations of AZT (1, 5, and 10 microM) for 4 h before viral inoculation and were maintained after infection in drug-containing medium. Establishment of viral infection was assessed by indirect immunofluorescence for viral antigens and by antigen capture assay carried out on culture fluids. AZT completely blocked infection in one of the HIV-1 variants studied; in the other two, treatment of cells with AZT significantly delayed the appearance of progeny virus.
- Published
- 1989
- Full Text
- View/download PDF
49. New CD4(+) cell line susceptible to infection by HIV-1.
- Author
-
Tremblay M, Sullivan AK, Rooke R, Geleziunas R, Tsoukas C, Shematek G, Gilmore N, and Wainberg MA
- Subjects
- Acquired Immunodeficiency Syndrome immunology, Acquired Immunodeficiency Syndrome microbiology, CD4-Positive T-Lymphocytes pathology, Cell Adhesion, Cell Line, Child, Cytopathogenic Effect, Viral, Genes, Viral, Genetic Markers, HIV Antigens, HIV-1 genetics, HIV-1 immunology, Humans, Immunity, Innate, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Tumor Cells, Cultured, Acquired Immunodeficiency Syndrome pathology, CD4-Positive T-Lymphocytes microbiology, HIV-1 growth & development, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology
- Abstract
Infection of a newly described human T lymphoid cell line, CEM-CL10, with three different variants of HIV-1 resulted in cytopathic effects followed by cell lysis. Following primary lytic infection, proviral DNA could not be detected by Southern blot analysis in the outgrowth of the surviving CEM-CL 10 cells 60 days after initial exposure to HIV-1. These surviving cells could be further grown as a separate line, derived from CEM-CL10, and were found to be resistant to subsequent infection by HIV-1. A marked decrease in CD4 antigen expression was observed in these latter cells but not of the CD3 and transferrin receptor antigens. This decline in cell surface CD4 expression was correlated with both an absence of specific CD4 mRNA and with changes in structure of the CD4 gene. Both the HIV-1-sensitive CEM-CL10 cell line and its CD4(-), HIV-1-resistant derivative line, will be made available to interested investigators.
- Published
- 1989
- Full Text
- View/download PDF
50. Susceptibility of EBV-carrying B cell lines to infection by HIV-1: variability of production of progeny virus and expression of viral antigens.
- Author
-
Tremblay M and Wainberg MA
- Subjects
- Cells, Cultured, HIV Antigens analysis, Herpesvirus 4, Human, Humans, RNA-Directed DNA Polymerase metabolism, Virus Replication, B-Lymphocytes microbiology, Cell Transformation, Viral, HIV-1 growth & development
- Abstract
We have examined 3 different EBV-carrying B cell lines, in terms of ability to be super-infected by the human immunodeficiency virus (HIV-1), and have followed these lines, after infection by HIV-1, over a period of 3 months. We found significant variation among different HIV-1 strains in terms of the multiplicity of infection required to initiate infection in these EBV-positive cell lines. Persistent infection by HIV-1 in the absence of detectable cytopathic effects could be demonstrated, as evaluated by a variety of techniques, including reverse transcriptase assay and immunofluorescence. The results indicate also that all of these cell lines produced progeny HIV-1 intermittently, with large amounts of virus production on some days but not others. In contrast, they were all able to continuously express p24.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.